BCDA
Price:
$2
Market Cap:
$9.17M
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscl...[Read more]
Industry
Biotechnology
IPO Date
1996-11-13
Stock Exchange
NASDAQ
Ticker
BCDA
According to BioCardia, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.50. This represents a change of -60.19% compared to the average of -1.26 of the last 4 quarters.
The mean historical PE Ratio of BioCardia, Inc. over the last ten years is -1.84. The current -0.50 PE Ratio has changed 2.61% with respect to the historical average. Over the past ten years (40 quarters), BCDA's PE Ratio was at its highest in in the June 2016 quarter at 9.49. The PE Ratio was at its lowest in in the June 2017 quarter at -25.65.
Average
-1.84
Median
-2.47
Minimum
-10.52
Maximum
8.69
Discovering the peaks and valleys of BioCardia, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 66.46%
Maximum Annual PE Ratio = 8.69
Minimum Annual Increase = -326.13%
Minimum Annual PE Ratio = -10.52
Year | PE Ratio | Change |
---|---|---|
2023 | -1.22 | -60.91% |
2022 | -3.11 | 19.55% |
2021 | -2.60 | 11.45% |
2020 | -2.33 | 66.46% |
2019 | -1.40 | -57.78% |
2018 | -3.32 | -54.44% |
2017 | -7.29 | -30.76% |
2016 | -10.52 | -326.13% |
2015 | 4.65 | -46.46% |
2014 | 8.69 | -88.62% |
The current PE Ratio of BioCardia, Inc. (BCDA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.31
5-year avg
-2.13
10-year avg
-1.84
BioCardia, Inc.’s PE Ratio is greater than Aerovate Therapeutics, Inc. (-0.89), greater than Adagene Inc. (-2.67), greater than Acrivon Therapeutics, Inc. Common Stock (-3.08), greater than Rezolute, Inc. (-4.44), greater than AN2 Therapeutics, Inc. (-0.67), greater than ZIVO Bioscience, Inc. (-5.50), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Erasca, Inc. (-4.56), greater than Forte Biosciences, Inc. (-1.06), less than Applied Molecular Transport Inc. (-0.43), greater than ABVC BioPharma, Inc. (-0.77), greater than Indaptus Therapeutics, Inc. (-0.58), less than Pasithea Therapeutics Corp. (-0.17), less than Better Therapeutics, Inc. (-0.00), greater than Anebulo Pharmaceuticals, Inc. (-5.30), greater than Mineralys Therapeutics, Inc. (-4.16), greater than NervGen Pharma Corp. (-9.10), less than Protagenic Therapeutics, Inc. (-0.39), greater than Miromatrix Medical Inc. (-7.13),
Company | PE Ratio | Market cap |
---|---|---|
-0.89 | $75.07M | |
-2.67 | $85.89M | |
-3.08 | $193.98M | |
-4.44 | $255.53M | |
-0.67 | $40.64M | |
-5.50 | $78.37M | |
-6.29 | $181.50M | |
-4.56 | $726.61M | |
-1.06 | $28.80M | |
-0.43 | $11.01M | |
-0.77 | $6.62M | |
-0.58 | $10.92M | |
-0.17 | $3.27M | |
-0.00 | $5.45K | |
-5.30 | $42.01M | |
-4.16 | $637.04M | |
-9.10 | $152.57M | |
-0.39 | $3.34M | |
-7.13 | $92.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioCardia, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioCardia, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BioCardia, Inc.'s PE Ratio?
How is the PE Ratio calculated for BioCardia, Inc. (BCDA)?
What is the highest PE Ratio for BioCardia, Inc. (BCDA)?
What is the 3-year average PE Ratio for BioCardia, Inc. (BCDA)?
What is the 5-year average PE Ratio for BioCardia, Inc. (BCDA)?
How does the current PE Ratio for BioCardia, Inc. (BCDA) compare to its historical average?